Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Algeta chooses Bayer as global partner for Alpharadin

Executive Summary

Norwegian biotech Algeta ASA has licensed Bayer Schering Pharma worldwide development and marketing rights to its Phase III cancer-targeting radiopharmaceutical Alpharadin (radium 223 chloride).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register